ANDA 60571, held by Delcor Asset Corp. Nystatin.
As of Nov 14, 2026, ANDA 60571 (Mycostatin), held by Delcor Asset Corp, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycostatin100,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท ointment;topical | Nystatin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
